Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.49 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1779691 | 0.84 | CYSLTR1 (0.49) | CYP1A2CYSLTR1CYSLTR2GPBAR1LMNA | |
| SCHEMBL5966250 | 0.80 | CYSLTR1 (0.49) | CYP1A2CYSLTR1CYSLTR2GPBAR1LMNA | |
| SCHEMBL1078145 | 0.80 | MEN1 (0.59) | CYP1A2CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL5090156 | 0.79 | CYP1A2 (0.45) | CYP1A2CYSLTR1CYSLTR2GPBAR1LMNA | |
| Bromide SCHEMBL27610232 | 0.78 | CYSLTR1 (0.47) | CYP1A2CYSLTR1CYSLTR2GPBAR1LMNA | |
| SCHEMBL243294 | 0.77 | CYSLTR1 (0.53) | CYP1A2CYSLTR1CYSLTR2GPBAR1LMNA | |
| SCHEMBL30879956 | 0.76 | CYSLTR1 (0.57) | CYP1A2CYSLTR1CYSLTR2LMNAPDE10A | |
| SCHEMBL2913941 | 0.76 | PDE10A (0.61) | CYP1A2CYSLTR1CYSLTR2PDE10ANCF1 | |
| SCHEMBL3267444 | 0.76 | CYSLTR1 (0.57) | CYP1A2CYSLTR1CYSLTR2LMNAPDE10A | |
| SCHEMBL1707992 | 0.76 | CYSLTR1 (0.57) | CYP1A2CYSLTR1CYSLTR2GPBAR1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206704-A1 | Pharmaceutically active diazepanes | Novartis AG (CH) | 2010-07-14 | — | — | EP | claimed |
| EP-1874739-A1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | Novartis AG (CH) | 2008-01-09 | — | — | EP | claimed |
| WO-2006111371-A1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | NOVARTIS AG (CH) | 2006-10-26 | — | — | WO | claimed |
| US-20040176309-A1 | Siglec inhibitors | KELM SORGE (DE) | 2004-09-09 | — | — | US | claimed |
| EP-1397374-A2 | SIGLEC INHIBITORS | Kelm, Sörge (DE) | 2004-03-17 | — | — | EP | claimed |
| WO-2003000709-A9 | SIALIC ACID DERIVATIVES FOR USE AS SIGLEC INHIBITORS | KELM SORGE (DE) | 2003-04-10 | — | — | WO | claimed |
| WO-2003000709-A2 | SIALIC ACID DERIVATIVES FOR USE AS SIGLEC INHIBITORS | KELM SORGE (DE) | 2003-01-03 | — | — | WO | claimed |
| EP-2275433-B1 | METASTIN DERIVATIVE AND USE THEREOF | UNIV KYOTO (JP) | 2017-06-07 | — | — | EP | disclosed |
| US-8778871-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8765909-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8592379-B2 | Metastin derivative and use thereof | KYOTO UNIVERSITY (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8361968-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20120015868-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
| US-5712274-A | ANTIINFLAMMATORY, ANTIALLERGEN | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-01-27 | — | — | US | disclosed |
| EP-0717736-A4 | POLAR-SUBSTITUTED HYDROCARBONS | NARHEX LTD (HK) | 1996-08-28 | — | — | EP | disclosed |
| EP-0717736-A1 | POLAR-SUBSTITUTED HYDROCARBONS | NARHEX LIMITED (HK) | 1996-06-26 | — | — | EP | disclosed |
| WO-1995007269-A1 | POLAR-SUBSTITUTED HYDROCARBONS | NARHEX LIMITED (HK) | 1995-03-16 | — | — | WO | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| US-4169150-A | MUSCLE RELAXANTS, HYPNOSIS, ANTICONVULSANTS, SEDATIVES | TEIJIN LIMITED (JP) | 1979-09-25 | — | — | US | disclosed |
| US-4138553-A | 3-Methylene cephalosporanic acid derivatives and process for preparation thereof | TEIJIN LIMITED (JP) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015868-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | CYP1A2 4794/4885CYSLTR1 3358/4885CYSLTR2 3086/4885 |
| US-20040176309-A1 | Siglec inhibitors | SIGLEC9, SIGLEC7, FCER2 | CYP1A2 2115/4885CYSLTR1 95/4885CYSLTR2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.